Abveris ANTI-IDIOTYPIC ANTIBODY DISCOVERY

ANTI-IDIOTYPIC ANTIBODY DISCOVERY SERVICES

With Abveris anti-idiotypic antibody discovery services, you get delivery of ideal anti-idiotypic monoclonal antibodies for PK/ADA assays using proprietary technology and industry-leading workflow.

WHAT ARE ANTI-IDIOTYPIC ANTIBODIES?

Anti-idiotypic antibodies are antibodies that bind to the antigen-binding site of another antibody or biologic. Anti-idiotypic antibodies are important downstream reagents for specific drug development assays (e.g. PK and ADA), as well as many other applications such as diagnostic assays and biomarker discovery & evaluation.

There are different ways an anti-idiotypic antibody can interact with an antibody via different regions (Figure 1). The key success factor for the development is the understanding of the intended applications and design of proper screening cascades for the selection of ideal anti-idiotypic antibodies. Abveris develops industry-leading technologies and workflows that will drastically enhance the success of anti-idiotypic antibody discovery campaigns.

Idiotope:

Antigenic determinant in & near CDRs

Paratope:

Part of antibody that recognizes antigen

Epitope:

Part of antigen to which paratope binds

Blocking & non-blocking anti-ids are useful for assay development.

FEATURES OF ABVERIS ANTI-IDIOTYPE DISCOVERY

Superior Antibody Diversity

Abveris's platform produces a diverse panel of specific anti-idiotypic antibodies using our proprietary hyperimmune DiversimAb^TM Mouse

Advanced Affinity and Specificity Screenings

Industry-leading stringent, function-forward screening package including BOTH Octet BLI and ELISA.
All delivered Anti-idiotype mAbs are screened for binding in the presence of human serum by ELISA and for affinity on Octet to deliver ideal mAbs for downstream use

Rapid, Predictable Project Timelines

Abveris devises an industry-leading anti-idiotypic antibody discovery platform that offers both single B cell screening and integrated hybridoma workflows to significantly de-risk projects and improves the predictability of timelines vs. other discovery workflows.

Proven Expertise and 96% Success Rate

100+ successful anti-idiotypic antibody programs
96% success rate based on project requirements
Success in different therapeutic modalities, including monoclonal antibodies, bispecifics, ADC, and cell therapy products such as CAR-T and CAT-NK

assays supported by anti-id_2

Selected Assays Supported by Abveris Anti-Idiotypic Antibodies

Download Anti-Id Discovery Handout

OUR ANTI-ID GUARANTEE:

Our anti-id guarantee promises delivery of anti-idiotypic antibodies capable of specific binding to target biologic. If we don’t find at least one, we will perform an additional screen for FREE.